Regeneron Pharmaceuticals Inc
(MEX:REGN)
MXN
18667
16.7 (0.09%)
Market Cap: 2.04 Tn
Enterprise Value: 1.90 Tn
PE Ratio: 24.59
PB Ratio: 3.63
GF Score: 92/100 Regeneron Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
May 30, 2023 / 04:30PM GMT
Release Date Price:
MXN13136.11
Tyler Martin Van Buren
TD Cowen, Research Division - MD & Senior Equity Research Analyst
All right. We'll give it a couple of seconds for everyone to join. Okay. So with that, welcome, everyone, again, to the TD Cowen's Fourth Annual Oncology Innovation Summit: Highlights for ASCO and EHA. My name is Tyler Van Buren, senior biotech analyst here at TD Cowen. For our next session, we're very pleased to have a fireside chat with Regeneron. And it's my sincere pleasure to introduce Izzy Lowy, Senior Vice President of Solid Organ Oncology Development; and Andreas Sirulnik, Senior Vice President of Heme-Onc Development. Izzy and Andreas, it's a privilege to have you both here. Thank you very much for joining me.
L. Andres Sirulnik
Regeneron Pharmaceuticals, Inc. - SVP of Translational & Clinical Sciences, Hematology
Thank you for having us, Tyler.
Tyler Martin Van Buren
TD Cowen, Research Division - MD & Senior Equity Research Analyst
Ryan, Head of IR -- Ryan Crowe, Head of IR, thank you very much for being
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot